Angiotensin-II
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Vasodilatory Shock
Conditions
Vasodilatory Shock
Trial Timeline
Sep 9, 2025 → Jun 1, 2030
NCT ID
NCT07212686About Angiotensin-II
Angiotensin-II is a approved stage product being developed by Innoviva for Vasodilatory Shock. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07212686. Target conditions include Vasodilatory Shock.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07212686 | Approved | Recruiting |
Other Products from Innoviva
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Ceftriaxone for Injection + Amoxicillin + Azithromcyin + clarithromycin + Clofazimine + Ethambutol + Amikacin Injection + tigecycline + Imipenem + Cilastatin + Cefoxitin + Amikacin (Inhalation) + linezolid + Trimethoprim / Sulfamethoxazole + Doxycycline + moxifloxacin + bedaquiline + RifabutinPhase 2
47
Eravacycline 2mg/kg + Eravacycline 1.5mg/kgPhase 2
47
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours) + Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours) + Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)Phase 1
28